Understanding how vaping affects blood vessels
Official title: Early Detection of Vaping-related Vascular Diseases
Run by University of Miami · NCT05454267 · Data updated 2026-11-12
This study looks at how vaping affects the blood vessels of adults aged 18-40 by comparing current e-cigarette users to healthy people who have never smoked or vaped.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 40 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University of Miami Academic / other |
| Locations | 1 site (Miami, Florida) |
| Status | Recruiting |
| Started | September 12, 2022 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT05454267 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18-40 who are current users of electronic cigarettes with a minimum nicotine concentration of 5% or healthy individuals who have never smoked or vaped.
✕Probably not a fit
Patients who smoke tobacco or other nicotine products, have chronic health issues, or are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the impact of vaping on blood vessels, specifically focusing on early damage that may occur in lung vessels. It will compare current electronic cigarette users with healthy individuals who have never smoked or vaped. Participants will be adults aged 18-40, and the study will gather data on their vascular health to assess the effects of vaping. The findings could provide insights into the risks associated with vaping and inform public health strategies.
Why it matters
Potential benefit: If successful, this study could help identify early vascular damage caused by vaping, leading to better prevention and treatment strategies.
How similar studies have gone: While there is limited research specifically on vaping-related vascular diseases, studies on smoking and vascular health have shown significant impacts, suggesting that this area of investigation is both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Vapers Group: 1. Current electronic cigarette (EC) Puff Bar users defined as using EC either daily or occasionally in the past 30 days for at least 6 months, and with 5% nicotine concentration pods. 2. Adults aged 18-40 years Healthy Group: 1. Healthy never smokers, never vapers 2. Adults aged 18-40 years Exclusion Criteria: 1. Current or past smoking of tobacco cigarette (TC) or other tobacco/nicotine products (e.g., smokeless tobacco, Hookah) or marijuana will be excluded from the study. 2. Subjects with self-reported history of chronic health problems including asthma, chronic obstructive pulmonary disease (COPD), morbid obesity (BMI\>40 kg/m2), hypertension or diabetes 3. Pregnant or breastfeeding women
Where it's running
-
University of Miami Health System
Miami, Florida, United States Recruiting
Study contacts
- Principal investigator: Adam Wanner, MD — University of Miami
- Study coordinator: Adam Wanner, MD
- Email: awanner@med.miami.edu
- Phone: (305)243-2568
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping
This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.
-
Social media support groups to help teens and young adults quit vaping
This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.
-
How synthetic nicotine and nicotine analogues behave in the body when vaped
This study tests synthetic nicotine and related nicotine analogues in vapes to see how they move through and act in the body compared with regular nicotine.
-
Varenicline plus enhanced TMS to help adults quit smoking and vaping
This study tests whether adding active enhanced accelerated transcranial magnetic stimulation (aTMS) to varenicline helps adults 18–65 quit nicotine use more effectively than varenicline with sham stimulation.
-
Varenicline to help adults stop vaping
This trial tests whether the smoking-cessation pill varenicline helps adults who vape daily quit e-cigarettes.
-
Using tDCS (mild brain stimulation) to reduce vaping
This project will try daily transcranial direct current stimulation (tDCS) to reduce cravings and vaping in adults who use nicotine e-cigarettes every day and are not planning to quit.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.